To Our New Jersey Life Sciences Community:
Welcome to another edition of The Weekender.
Following on the recent Annual Meeting Celebration of Innovators that had recent drug approvals, congratulations to Celgene Corporation for its announcement that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM). Also, congratulations to Eisai, for its approval of an additional pediatric indication for its antiepileptic drug, Banzel (rufinamide). Clearly, New Jersey continues to be a place where Drugs are Developed.
March 9-13 marks New Jersey STEM week. Hug a STEM teacher today!
Click here to read this week’s Weekender.